Lycoremin

• Nootropic Agents
• Parasympathomimetics
• ATC:N06DA04

• Galantamin
• Galanthamine
• Galanthamine base
• Galanthamine hydrobromide
• Jilkon
• Lycoremin
• Lycoremine
• Reminyl

• No information avaliable

C₁₇H₂₁NO₃

http://www.rxlist.com/cgi/generic/reminyl.htm

Lycoremin FDA

Lycoremin MSDS

Czollner, L. et al. ARKIVOC 191-200 (2001).

287.354 g/mol

269-270 ^oC (HBr salt)

10 mg/mL (HBr salt)

Solid

2.369

Capsules (extended-release)

For the treatment of mild to moderate dementia of the Alzheimer's type.

Galantamine is a parasympathomimetic, specifically, a reversible cholinesterase inhibitor. Galantamine is indicated for the treatment of mild to moderate dementia of the Alzheimer's type. Galantamine is postulated to exert its therapeutic effect by enhancing cholinergic function. This is accomplished by increasing the concentration of acetylcholine through reversible inhibition of its hydrolysis by acetylcholinesterase. If this proposed mechanism of action is correct, Galantamine's effect may lessen as the disease process advances and fewer cholinergic neurons remain functionally intact. There is no evidence that Galantamine alters the course of the underlying dementing process.

No information avaliable

LD₅₀=75 mg/kg (rat)

Galantamine is used to treat the symptoms of Alzheimer's disease (AD; a brain disease that slowly destroys the memory and the ability to think, learn, communicate and handle daily activities). Galantamine is in a class of medications called acetylcholinesterase inhibitors. It works by increasing the amount of a certain natural substance in the brain that is needed for memory and thought. Galantamine may improve the ability to think and remember or slow the loss of these abilities in people who have AD. However, galantamine will not cure AD or prevent the loss of mental abilities at some time in the future.

Humans and other mammals